Sutent, made by Pfizer Canada Inc., is used to treat cancers of the stomach and bowels, kidney, and pancreas.
In a Health Canada advisory Friday, the company said Sutent (sunitinib malate) has been associated in some people with severe skin rashes, among them Stevens-Johnson syndrome and toxic epidermal necrolysis.
Symptoms of severe skin reactions may initially appear as reddish target-like spots or circular patches, often with central blisters on the trunk, or elsewhere on the body.
The rash may progress to widespread blistering or peeling of the skin, blisters in the mouth and ulcers in the eyes. The skin changes happen quickly and may follow fever, fatigue, headache and cough.
If such symptoms occur, patients should stop taking the drug and contact their health-care provider immediately, Health Canada said.
Cases of toxic epidermal necrolysis and Stevens-Johnson syndrome have been very rarely reported in patients who have used Sutent. However, some cases have resulted in death.